Intellia Therapeutics Inc
NTLA
Market Cap$2.52B
Close$
$-4.64
117.7% downside
Current Fair Value
117.7% downsideOvervalued by 117.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.52 Billion |
|---|---|
| Enterprise Value | $1.73 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-5.35 |
| Beta | 2.1 |
| Outstanding Shares | 96,475,421 |
| Avg 30 Day Volume | 1,321,039 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.2 |
|---|---|
| PEG | -124.43 |
| Price to Sales | - |
| Price to Book Ratio | 2.62 |
| Enterprise Value to Revenue | 32.95 |
| Enterprise Value to EBIT | -3.27 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Intellia Therapeutics Inc
211 employees
CEO: John Leonard Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Th...